" We’re going to be cutting regulations at a level that nobody’s ever seen before, and we’re going to have tremendous protection for the people. " Some have suggested that a commissioner determined to weaken the efficacy standard need not seek congressional action, but could interpret existing regulations loosely so that requirements for certain clinical trials  —   particularly the costly,   ones that can take years and involve thousands of patients   